Sander Strengholt

665 total citations
22 papers, 455 citations indexed

About

Sander Strengholt is a scholar working on Rheumatology, Genetics and Hematology. According to data from OpenAlex, Sander Strengholt has authored 22 papers receiving a total of 455 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Rheumatology, 9 papers in Genetics and 7 papers in Hematology. Recurrent topics in Sander Strengholt's work include Rheumatoid Arthritis Research and Therapies (19 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Autoimmune and Inflammatory Disorders Research (7 papers). Sander Strengholt is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (19 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Autoimmune and Inflammatory Disorders Research (7 papers). Sander Strengholt collaborates with scholars based in United States, Germany and United Kingdom. Sander Strengholt's co-authors include Jeffrey R. Curtis, Lisy Wang, Ketti K. Terry, Irina Lazariciu, J. Wollenhaupt, Kenneth Kwok, Ryan DeMasi, Joel C. Silverfield, Stanley Cohen and Koshika Soma and has published in prestigious journals such as Annals of the Rheumatic Diseases, Lara D. Veeken and Arthritis Research & Therapy.

In The Last Decade

Sander Strengholt

19 papers receiving 441 citations

Peers

Countries citing papers authored by Sander Strengholt

Since Specialization

Citations

This map shows the geographic impact of Sander Strengholt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sander Strengholt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sander Strengholt more than expected).

Fields of papers citing papers by Sander Strengholt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sander Strengholt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sander Strengholt. The network helps show where Sander Strengholt may publish in the future.

Co-authorship network of co-authors of Sander Strengholt

This figure shows the co-authorship network connecting the top 25 collaborators of Sander Strengholt. A scholar is included among the top collaborators of Sander Strengholt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sander Strengholt. Sander Strengholt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study 2025 ·Arthritis Research & Therapy ·Andrew J.K. Östör, Eugen Feist, Prodromos Sidiropoulos, Jérôme Avouac, (unknown), Rajaie Namas, (unknown), (unknown), (unknown), Sander Strengholt, Devy Zisman, Suzan Attar	2
2	Benefit–risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease 2025 ·RMD Open ·Gerd R Burmester, Eduardo Mysler, Peter C. Taylor, Stephen Hall, (unknown), (unknown), Tianming Gao, (unknown), Sander Strengholt, Roy Fleischmann	1
3	A Real-World Comparison of Clinical Effectiveness in Patients with Rheumatoid Arthritis Treated with Upadacitinib, Tumor Necrosis Factor Inhibitors, and Other Advanced Therapies After Switching from an Initial Tumor Necrosis Factor Inhibitor 2024 ·Advances in Therapy ·Roberto Caporali, Aditi Kadakia, (unknown), (unknown), (unknown), Sander Strengholt, (unknown), Peter C. Taylor	2
4	POS0653 ACHIEVEMENT AND MAINTENANCE OF REMISSION WITH UPADACITINIB IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS IN A REAL-WORLD SETTING: 1-YEAR OUTCOMES FROM THE UPHOLD STUDY 2024 ·Annals of the Rheumatic Diseases ·A. J. Ostor, Eugen Feist, (unknown), Jérôme Avouac, (unknown), Rajaie Namas, (unknown), (unknown), (unknown), Sander Strengholt, S Attar	0
5	Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme 2023 ·Annals of the Rheumatic Diseases ·Roy Fleischmann, Jeffrey R. Curtis, Christina Charles‐Schoeman, Eduardo Mysler, Kunihiro Yamaoka, Christophe Richez, Hannah Palac, (unknown), Jianzhong Liu, Sander Strengholt, Gerd R Burmester	34
6	Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases 2023 ·Lara D. Veeken ·Peter C. Taylor, Ernest Choy, Xenofon Baraliakos, Zoltán Szekanecz, Ricardo Machado Xavier, John D. Isaacs, Sander Strengholt, Julie Parmentier, Ralph Lippe, Yoshiya Tanaka	45
7	Opportunistische Infektionen im Zusammenhang mit der Behandlung von rheumatoider Arthritis mit Januskinase-Inhibitoren: eine strukturierte Literaturübersicht 2023 ·Kevin Winthrop, John D. Isaacs, Leonard H. Calabrese, (unknown), (unknown), (unknown), Sander Strengholt, James Galloway	0
8	Opportunistic infections associated with Janus kinase inhibitor treatment for rheumatoid arthritis: A structured literature review 2022 ·Seminars in Arthritis and Rheumatism ·Kevin Winthrop, John D. Isaacs, Leonard H. Calabrese, (unknown), (unknown), (unknown), Sander Strengholt, James Galloway	13
9	Mise à jour de l’analyse intégrée de la tolérance du filgotinib (FIL) chez les patients atteints de polyarthrite rhumatoïde (PR) active modérée à sévère recevant un traitement (TT) sur une période médiane de 2,2 ans 2022 ·Revue du Rhumatisme ·Jacques‐Eric Gottenberg, Kevin Winthrop, Yoshiya Tanaka, Tsutomu Takeuchi, Gerd R Burmester, Alan Kivitz, Mark C. Genovese, (unknown), F. Matzkies, Beatrix Bartók, (unknown), Deyuan Jiang, (unknown), R. Besuyen, Sander Strengholt	1
10	POS0660 CONCOMITANT USE OF STATINS IN FILGOTINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS 2021 ·Annals of the Rheumatic Diseases ·Peter C. Taylor, Christina Charles‐Schoeman, (unknown), Madhukar H. Trivedi, V. Castellano, (unknown), Deyuan Jiang, (unknown), Sander Strengholt, Michael T. Nurmohamed, Gerd R Burmester	2
11	Assessment of radiographic progression in patients with rheumatoid arthritis treated with tofacitinib in long-term studies 2020 ·Lara D. Veeken ·Désirée van der Heijde, Robert Landewé, J. Wollenhaupt, Sander Strengholt, Ketti K. Terry, Kenneth Kwok, Lisy Wang, Stanley Cohen	5
12	Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study 2019 ·Arthritis Research & Therapy ·J. Wollenhaupt, (unknown), Jeffrey R. Curtis, Joel C. Silverfield, Ketti K. Terry, Koshika Soma, (unknown), Ryan DeMasi, Sander Strengholt, Kenneth Kwok, Irina Lazariciu, Lisy Wang, Stanley Cohen	238
13	SAT0234 Tofacitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 9 years 2018 ·Annals of the Rheumatic Diseases ·J. Wollenhaupt, Joel C. Silverfield, (unknown), Ketti K. Terry, Kenneth Kwok, Sander Strengholt, Ryan DeMasi, (unknown)	22
14	Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry 2018 ·Lara D. Veeken ·Inge Christoffer Olsen, Elisabeth Lie, Radu Vasilescu, Gene V. Wallenstein, Sander Strengholt, Tore K Kvien	17
15	Evaluation of the Short‐, Mid‐, and Long‐Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis 2018 ·Arthritis & Rheumatology ·Ronald van Vollenhoven, Eun Bong Lee, Sander Strengholt, Christopher F. Mojcik, Hernán Valdez, Sriram Krishnaswami, Pinaki Biswas, Irina Lazariciu, Anasuya Hazra, James D. Clark, Jennifer Hodge, Lisy Wang, Ernest Choy	38
16	Assessment of Radiographic Progression in Patients with Rheumatoid Arthritis Treated with Tofacitinib: Data from an Open-Label Long-Term Extension Study over 3 Years 2017 ·Arthritis & Rheumatism ·D. van der Heijde, J. Wollenhaupt, Stanley Cohen, Sander Strengholt, Ketti K. Terry, Ryan DeMasi, Kenneth Kwok, Irina Lazariciu, (unknown)	3
17	THU0185 Comparison of tofacitinib safety and efficacy in rheumatoid arthritis patients with inadequate response to conventional synthetic dmards, or to one or more biological dmards 2017 ·Annals of the Rheumatic Diseases ·Christina Charles‐Schoeman, Joel M. Kremer, S. Krishnaswami, (unknown), Jamie Geier, Richard Zhang, Sander Strengholt, (unknown)	2
18	Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials 2016 ·Arthritis Research & Therapy ·Robert Landewé, Carol A. Connell, John Bradley, Bethanie Wilkinson, David Gruben, Sander Strengholt, Désirée van der Heijde	24
19	Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib 2016 ·Clinical Rheumatology ·Jeffrey R. Curtis, Richard Zhang, Sriram Krishnaswami, Andrew M. Anisfeld, Yan Chen, Sander Strengholt, Connie Chen, Jamie Geier	4
20	SAT0220 Radiographic Progression in Modern RA Trials is Still a Robust Outcome: Results of Comprehensive Sensitivity Analysis in Two Phase 3 Trials with Tofacitinib 2015 ·Annals of the Rheumatic Diseases ·D. van der Heijde, Carol A. Connell, John Bradley, David Gruben, Sander Strengholt, Robert Landewé	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact